Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor.

Li PK, Kwan BC, Chow KM, Leung CB, Szeto CC.

Am J Med. 2013 Feb;126(2):162-8. doi: 10.1016/j.amjmed.2012.06.028.

PMID:
23331443
[PubMed - indexed for MEDLINE]
2.

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.

Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G.

Am J Kidney Dis. 2000 Jun;35(6):1155-65.

PMID:
10845831
[PubMed - indexed for MEDLINE]
4.

Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.

Manno C, Torres DD, Rossini M, Pesce F, Schena FP.

Nephrol Dial Transplant. 2009 Dec;24(12):3694-701. doi: 10.1093/ndt/gfp356. Epub 2009 Jul 23. Erratum in: Nephrol Dial Transplant. 2010 Apr;25(4):1363-4.

PMID:
19628647
[PubMed - indexed for MEDLINE]
Free Article
5.
6.

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.

Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G.

Lancet. 1999 Jul 31;354(9176):359-64.

PMID:
10437863
[PubMed - indexed for MEDLINE]
7.

Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.

Cruzado JM, Poveda R, Ibernón M, Díaz M, Fulladosa X, Carrera M, Torras J, Bestard O, Navarro I, Ballarín J, Romero R, Grinyó JM.

Nephrol Dial Transplant. 2011 Nov;26(11):3596-602. doi: 10.1093/ndt/gfr072. Epub 2011 Mar 10.

PMID:
21393611
[PubMed - indexed for MEDLINE]
Free Article
8.

ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study.

Pozzi C, Del Vecchio L, Casartelli D, Pozzoni P, Andrulli S, Amore A, Peruzzi L, Coppo R, Locatelli F; Adulto e Bambino Study Group; Immunopatologia Renale Study Group of the Italian Society of Nephrology.

J Nephrol. 2006 Jul-Aug;19(4):508-14.

PMID:
17048209
[PubMed - indexed for MEDLINE]
9.

Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.

Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, Kohno S.

Hypertens Res. 2004 Dec;27(12):963-70.

PMID:
15894837
[PubMed - indexed for MEDLINE]
Free Article
10.

Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study.

Li PK, Chow KM, Wong TY, Leung CB, Szeto CC.

Ann Intern Med. 2003 Jul 15;139(2):105-12.

PMID:
12859160
[PubMed - indexed for MEDLINE]
11.

Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.

Moriyama T, Amamiya N, Ochi A, Tsuruta Y, Shimizu A, Kojima C, Itabashi M, Takei T, Uchida K, Nitta K.

Clin Exp Nephrol. 2011 Oct;15(5):700-7. doi: 10.1007/s10157-011-0455-8. Epub 2011 May 31.

PMID:
21625892
[PubMed - indexed for MEDLINE]
12.

Can young adult patients with proteinuric IgA nephropathy perform physical exercise?

Fuiano G, Mancuso D, Cianfrone P, Comi N, Mazza G, Marino F, Fuiano L, Zamboli P, Caglioti A, Andreucci M.

Am J Kidney Dis. 2004 Aug;44(2):257-63.

PMID:
15264183
[PubMed - indexed for MEDLINE]
13.

Comparison of inhibitors of renin-angiotensin-aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function.

Moriyama T, Nakayama K, Ochi A, Amemiya N, Tsuruta Y, Kojima C, Itabashi M, Takei T, Uchida K, Nitta K.

Clin Exp Nephrol. 2012 Apr;16(2):231-7. doi: 10.1007/s10157-011-0545-7. Epub 2011 Oct 26.

PMID:
22038185
[PubMed - indexed for MEDLINE]
14.

Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.

Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC; HKVIN Study Group.

Am J Kidney Dis. 2006 May;47(5):751-60.

PMID:
16632013
[PubMed - indexed for MEDLINE]
15.

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.

Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL.

Arch Intern Med. 2005 Apr 25;165(8):947-53.

PMID:
15851648
[PubMed - indexed for MEDLINE]
16.

Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.

Ruggenenti P, Perna A, Remuzzi G; GISEN Group Investigators.

Kidney Int. 2003 Jun;63(6):2254-61.

PMID:
12753315
[PubMed - indexed for MEDLINE]
17.

[Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors].

Erley CM, Berger ED, Heyne N, Klass M, Krämer D, Braun N, Wolf S, Risler T.

Dtsch Med Wochenschr. 1997 Aug 1;122(31-32):953-8. German.

PMID:
9280714
[PubMed - indexed for MEDLINE]
18.

ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.

Ruggenenti P, Perna A, Remuzzi G; Gruppo Italiano di Studi Epidemiologici in Nefrologia.

J Am Soc Nephrol. 2001 Dec;12(12):2832-7.

PMID:
11729254
[PubMed - indexed for MEDLINE]
Free Article
19.

In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia.

Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C, Maggiore Q, Salvadori M, Remuzzi G.

J Am Soc Nephrol. 1999 May;10(5):997-1006.

PMID:
10232685
[PubMed - indexed for MEDLINE]
Free Article
20.

Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.

Luna E, Cerezo I, Macias R, Villa J, Martinez C, Cubero J, Martinez R, Ferreira F, García C.

Transplant Proc. 2011 Jul-Aug;43(6):2187-90. doi: 10.1016/j.transproceed.2011.06.055.

PMID:
21839229
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk